An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis.

Affiliation

Internal Medicine, Rheumatology Division, Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 800, Dallas, TX, 75231, USA. [Email]

Abstract

ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA).

Keywords

ABP 501,Adalimumab,Biosimilar,Efficacy,Long-term safety,Rheumatoid arthritis,

OUR Recent Articles